| III-47 Jurij Aguiar Zdovc Model-based individualization of ustekinumab dosing in Crohn's disease |
| III-48 Orwa Albitar A Pharmacokinetic and Pharmacodynamic Model of Cyclosporine among Malaysian Renal Transplant Patients |
| III-49 Muhammad Waqar Ashraf A population pharmacokinetic model to quantify the role of in-vivo CYP2D6 activity in codeine metabolism for model informed precision dosing in ambulatory surgical patients. |
| III-50 Rebecca Baillie Reuse of a published model to support compassionate use of novel drug formulation for a rare disorder |
| III-51 Amina Bensalem The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition |
| III-52 Rene Boosman The pemetrexed exposure-neutropenia relationship, paving the way to a safe administration in patients with an impaired renal function |
| III-53 Divakar Budda Prediction of CNS Target Engagement of Pain reliving Drugs in Health and Chronic Pain conditions |
| III-54 Laura Bukkems Population pharmacokinetics of Haemate P describing the interaction between factor VIII and Von Willebrand Factor levels in perioperative patients with von Willebrand Disease |
| III-55 Vera Bukkems A combined modelling approach to assess the efficacy and safety of doravirine in pregnant women |
| III-56 Elisa Calvier TMDD model to extrapolate free target reduction from competitor data in healthy volunteers to another drug in patients in order to select active dose range for phase II trials |
| III-57 Fernando Carreño Modelling of Dose-Response-Time Data Using a Population k-PD approach for Linerixibat, a Locally Acting Small Molecule with Minimal Systemic Absorption |
| III-58 Myriam Chartoire Development of mechanistic models for analysis and interpretation of cough challenge test data |
| III-59 Perrine Courlet Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control |
| III-60 Wilbert de Witte Continuous Time Markov Modelling in Systemic Lupus Erythematosus |
| III-61 Tayebeh Esmaeili Rivaroxaban Population Pharmacokinetics Modeling in Iranian Patients |
| III-62 Yu Fu A novel hemodynamic systems model to quantify pharmacodynamic effects on heart rate and contractility |
| III-63 Frédéric Gaspar A step towards Ticagrelor individualization based on pharmacokinetic approaches: which place for Physiologically-Based Modelling? |
| III-64 Mélanie Guhl Model-based analysis of PK equivalence: assessing the impact of model misspecification |
| III-65 Khalid Iqbal A PK-PD modelling and simulation-based evaluation of tedizolid dosing strategies for immunocompromised patients |
| III-67 Ranita Kirubakaran Matters close to the heart: adaptation of a tacrolimus model to inform tacrolimus therapy using the PRIOR approach |
| III-68 Christine Juliane Kleist Homoarginine population kinetics |
| III-69 Jane Knöchel Markov model demonstrates the importance of fibrosis distribution on clinical trial design in NAFLD/NASH |
| III-70 Niklas Kroemer Development and evaluation of D-optimal 2x2 checkerboard designs for identification of pharmacodynamic drug interactions |
| III-71 Julia Larsson A second-generation challenge model of TNFa turnover with LPS provocations and drug intervention |
| III-72 Li Li Model-Based Approach for assessing the Effect of Anti-Drug Antibodies on the PK of Therapeutic Proteins |
| III-73 Qiang Lu Semi-mechanistic Population Pharmacokinetic/Pharmacodynamic (Pop PK/PD) Modeling of Dupilumab on Nasal Congestion (NC) Score in Patients with Chronic Rhinosinusitis with Nasal Polyposis |
| III-74 Bastien Martin In silico clinical trial simulation shows amelioration of ischemia-reperfusion injury in ST-elevation myocardial infarction via inhibition of reactive oxygen species production |
| III-75 Saikumar Matcha Population Pharmacokinetics of Unbound Phenytoin after Administration of IV Fosphenytoin And Oral Phenytoin in Pediatric Patients. |
| III-76 Nicola Melillo Development and validation of a physiologically-based pharmacokinetic model of the imaging biomarker gadoxetate for prospective prediction of hepatic transporters drug-drug interactions |
| III-77 Yomna Nassar Quantifying the dynamics of the modulatory effect of CYP3A perpetrators on hepatic CYP3A activity using a nonlinear mixed-effects model of microdosed midazolam and its metabolite 1-hydroxymidazolam |
| III-78 Karine Rodriguez-Fernandez Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics |
| III-79 Benjamin Schneider A Quantitative Systems Pharmacology Model for Bedside Optimization of ACE Inhibitor Dose Scheduling in Veterinary Cardiology |
| III-80 Daniel Seeler Towards understanding vascular (dys)regulation by linking endothelial cell morphology and blood vessel geometry |
| III-81 Sejung Hwang Effect of CYP2D6 genotype on pharmacokinetics and pharmacodynamics of carvedilol for the heart rate reduction in healthy subjects |
| III-82 Manna Semere Gebreyesus Population pharmacokinetics of esomeprazole in pregnant women with preterm preeclampsia |
| III-83 Monica Simeoni A Model Based Meta-Analysis for Bridging Treatment Doses of Rheumatoid Arthritis with Axial Spondyloarthritis |
| III-84 Leonid Stolbov A QSP approach to investigate the glucose-insulin dynamic following dapagliflozin treatment in patients with type 2 diabetes mellitus |
| III-85 David Ternant In-depth description of target-mediated pharmacokinetics of infliximab in inflammatory bowel disease patients |
| III-86 Wisse van Os Targeted temperature management reduces CYP2C19 metabolism: a population pharmacokinetic study using pantoprazole |
| III-87 Zhigang Wang Pharmacokinetic-Pharmacodynamic Model-Based Exploration of Alternative Ustekinumab Dosage Regimens for Patients with Crohn’s Disease |
| III-88 Liang Yang A quantitative pharmacology model for CB1 receptor mediated by Gi Gs protein competition |
| III-89 Miren Zamacona Population pharmacokinetic and exposure-response models for dapirolizumab pegol in patients with systemic lupus erythematosus |
| III-90 Chiara Zecchin mPBPK and PD modelling and simulation to predict drug and pharmacodynamic effect at site of action and guide the design of a phase 2A/B study |
